Halozyme Therapeutics, Inc.
HALO
$62.54
-$0.41-0.65%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 29.55% | 34.28% | 4.67% | 20.81% | 26.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.55% | 34.28% | 4.67% | 20.81% | 26.75% |
| Cost of Revenue | -15.13% | -5.90% | -13.11% | -10.74% | 13.83% |
| Gross Profit | 50.58% | 54.42% | 12.87% | 36.19% | 33.90% |
| SG&A Expenses | 12.34% | 16.93% | -8.31% | -5.95% | 137.29% |
| Depreciation & Amortization | 0.00% | -0.44% | -0.41% | -0.40% | 290.20% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.04% | 1.30% | -9.85% | -7.39% | 51.61% |
| Operating Income | 73.70% | 79.77% | 24.11% | 77.58% | 4.80% |
| Income Before Tax | 76.14% | 62.29% | 26.39% | 83.83% | 42.92% |
| Income Tax Expenses | 160.99% | 41.22% | 33.13% | 52.14% | 20.61% |
| Earnings from Continuing Operations | 60.46% | 67.42% | 24.74% | 93.92% | 47.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.46% | 67.42% | 24.74% | 93.92% | 47.98% |
| EBIT | 73.70% | 79.77% | 24.11% | 77.58% | 4.80% |
| EBITDA | 61.52% | 65.66% | 19.69% | 56.94% | 17.81% |
| EPS Basic | 63.83% | 74.18% | 29.25% | 106.27% | 55.12% |
| Normalized Basic EPS | 81.90% | 88.66% | 30.97% | 94.19% | 13.57% |
| EPS Diluted | 62.31% | 72.13% | 28.57% | 106.90% | 54.62% |
| Normalized Diluted EPS | 81.01% | 86.86% | 30.62% | 95.27% | 14.61% |
| Average Basic Shares Outstanding | -2.05% | -3.88% | -3.50% | -5.99% | -4.61% |
| Average Diluted Shares Outstanding | -1.57% | -2.95% | -3.24% | -6.54% | -5.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
